tbuckley/cabot-search huggingface dataset:
AASLD Practice Guidance on risk stratification and management of portal hypertension and varices in cirrhosis
Authors: David E. Kaplan, Cristina Ripoll, Maja Thiele, Brett E. Fortune, Douglas A. Simonetto, Guadalupe Garcia-Tsao, Jaime Bosch
Journal: Hepatology (2023)

Kaplan, David E.; Bosch, Jaime; Ripoll, Cristina; Thiele, Maja; Fortune, Brett E.; Simonetto, Douglas A.; Garcia-Tsao, Guadalupe Author Information
Association of hepatitis delta virus with liver morbidity and mortality: A systematic literature review and meta-analysis
Authors: Robert G. Gish, Robert J. Wong, Gian Luca Di Tanna, Ankita Kaushik, Chong Kim, Nathaniel J. Smith, Patrick T.F. Kennedy
Journal: Hepatology (2023)

Background and Aims: Studies have suggested that patients with chronic hepatitis B, either co- or superinfected, have more aggressive liver disease progression than those with the HDV. This systematic literature review and meta-analysis examined whether HDV RNA status is associated with increased risk of advanced liver disease events in patients who are HBsAg and HDV antibody positive. Approach and Results: A total of 12 publications were included. Relative rates of progression to advanced liver disease event for HDV RNA+/detectable versus HDV RNA−/undetectable were extracted for analysis. Reported OR and HRs with 95% CI were pooled using the Hartung-Knapp-Sidik-Jonkman method for random-effects models. The presence of HDV RNA+ was associated with an increased risk of any advanced liver disease event [random effect (95% CI): risk ratio: 1.48 (0.93, 2.33); HR: 2.62 (1.55, 4.44)]. When compared to the patients with HDV RNA− status, HDV RNA+ was associated with a significantly higher risk of progressing to compensated cirrhosis [risk ratio: 1.74 (1.24, 2.45)] decompensated cirrhosis [HR: 3.82 (1.60, 9.10)], HCC [HR: 2.97 (1.87, 4.70)], liver transplantation [HR: 7.07 (1.61, 30.99)], and liver-related mortality [HR: 3.78 (2.18, 6.56)]. Conclusions: The patients with HDV RNA+ status have a significantly greater risk of liver disease progression than the patients who are HDV RNA−. These findings highlight the need for improved HDV screening and linkage to treatment to reduce the risk of liver-related morbidity and mortality.
Effects of an online information tool on post-traumatic stress disorder in relatives of intensive care unit patients: a multicenter double-blind, randomized, placebo-controlled trial (ICU-Families-Study)
Authors: Magdalena Hoffmann, Marie-Madlen Jeitziner, Regina Riedl, Gerhard Mueller, Andreas Peer, Adelbert Bachlechner, Patrik Heindl, Harald Burgsteiner, Joerg C. Schefold, Dirk von Lewinski, Philipp Eller, Thomas Pieber, Gerald Sendlhofer, Karin Amrein
Journal: Intensive Care Medicine (2023)

Intensive care unit (ICU) hospitalization is challenging for the family members of the patients. Most family members report some level of anxiety and depression, sometimes even resulting in post-traumatic stress disorder (PTSD). An association has been reported between lack of information and PTSD. This study had three aims: to quantify the psychological burden of family members of critically ill patients, to explore whether a website with specific information could reduce PTSD symptoms, and to ascertain whether a website with information about intensive care would be used. A multicenter double-blind, randomized, placebo-controlled trial was carried out in Austria and Switzerland. In total, 89 members of families of critically ill patients (mean age 47.3 ± 12.9 years, female n = 59, 66.3%) were included in the study. 46 relatives were allocated to the intervention website and 43 to the control website. Baseline Impact of Event Scale (IES) score was 27.5 ± 12.7. Overall, 50% showed clinically relevant PTSD symptoms at baseline. Mean IES score for the primary endpoint (~ 30 days after inclusion, T1) was 24 ± 15.8 (intervention 23.9 ± 17.9 vs. control 24.1 ± 13.5, p = 0.892). Hospital Anxiety and Depression Scale (HADS - Deutsch (D)) score at T1 was 12.2 ± 6.1 (min. 3, max. 31) and did not differ between groups. Use of the website differed between the groups (intervention min. 1, max. 14 vs. min. 1, max. 3; total 1386 "clicks" on the website, intervention 1021 vs. control 365). Recruitment was prematurely stopped in February 2020 due to coronavirus disease 2019 (COVID-19). Family members of critically ill patients often have significant PTSD symptoms and online information on critical illness did not result in reduced PTSD symptoms.
Nirmatrelvir and Molnupiravir and Post–COVID-19 Condition in Older Patients
Authors: Kin Wah Fung, Fitsum Baye, Seo H. Baik, Clement J. McDonald
Journal: JAMA Internal Medicine (2023)

This observational cohort study assesses the occurrence of post–COVID-19 condition symptoms in Medicare enrollees prescribed nirmatrelvir and molnupiravir.
The macrophage STING-YAP axis controls hepatic steatosis by promoting the autophagic degradation of lipid droplets
Authors: Tao Yang, Xiaoye Qu, Xiao Wang, Dongwei Xu, Mingwei Sheng, Yuanbang Lin, Michael Ke, Ci Song, Qiang Xia, Longfeng Jiang, Jun Li, Douglas G. Farmer, Bibo Ke
Journal: Hepatology (2023)

Background and Aims: The hallmark of NAFLD or hepatic steatosis is characterized by lipid droplet (LD) accumulation in hepatocytes. Autophagy may have profound effects on lipid metabolism and innate immune response. However, how innate immune activation may regulate the autophagic degradation of intracellular LDs remains elusive. Approach and Results: A mouse model of a high-fat diet–induced NASH was used in the myeloid-specific stimulator of interferon genes (STING) knockout or STING/yes-associated protein (YAP) double knockout mice. Liver injury, lipid accumulation, lipid droplet proteins, autophagic genes, chromatin immunoprecipitation coupled with massively parallel sequencing, and RNA-Seq were assessed in vivo and in vitro . We found that high-fat diet–induced oxidative stress activates STING and YAP pathways in hepatic macrophages. The acrophage STING deficiency (myeloid-specific STING knockout) enhances nuclear YAP activity, reduces lipid accumulation, and increases autophagy-related proteins ATG5, ATG7, and light chain 3B but diminishes LD protein perilipin 2 expression. However, disruption of STING and YAP (myeloid STING and YAP double knockout) increases serum alanine aminotransferase and triglyceride levels and reduces β-fatty acid oxidation gene expression but augments perilipin 2 levels, exacerbating high-fat diet–induced lipid deposition. Chromatin immunoprecipitation coupled with massively parallel sequencing reveals that macrophage YAP targets transmembrane protein 205 and activates AMP-activated protein kinase α, which interacts with hepatocyte mitofusin 2 and induces protein disulfide isomerase activation. Protein disulfide isomerase activates hypoxia-inducible factor-1α signaling, increases autophagosome colocalization with LDs, and promotes the degradation of perilipin 2 by interacting with chaperone-mediated autophagy chaperone HSC70. Conclusions: The macrophage STING-YAP axis controls hepatic steatosis by reprogramming lipid metabolism in a transmembrane protein 205/mitofusin 2/protein disulfide isomerase-dependent pathway. These findings highlight the regulatory mechanism of the macrophage STING-driven YAP activity on lipid control.
Error in Weighted Analyses and Reported Prevalence Rates
Authors: Amanda E. Staiano
Journal: JAMA Pediatrics (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
A newly identified ferritin <scp>L</scp>‐subunit variant results in increased proteasomal subunit degradation, impaired complex assembly, and severe hypoferritinemia
Authors: Dayana Shagidov, Noga Guttmann‐Raviv, Séverine Cunat, Liora Frech, Muriel Giansily‐Blaizot, Niraj Ghatpande, Gili Abelya, Gabriel A. Frank, Patricia Aguilar Martinez, Esther G. Meyron‐Holtz
Journal: American Journal of Hematology (2023)

Abstract Ferritin is a hetero‐oligomeric nanocage, composed of 24 subunits of two types, FTH1 and FTL. It protects the cell from excess reactive iron, by storing iron in its cavity. FTH1 is essential for the recruitment of iron into the ferritin nanocage and for cellular ferritin trafficking, whereas FTL contributes to nanocage stability and iron nucleation inside the cavity. Here we describe a female patient with a medical history of severe hypoferritinemia without anemia. Following inadequate heavy IV iron supplementation, the patient developed severe iron overload and musculoskeletal manifestations. However, her serum ferritin levels rose only to normal range. Genetic analyses revealed an undescribed homozygous variant of FTL (c.92A &gt; G), which resulted in a Tyr31Cys substitution (FTL Y31C ). Analysis of the FTL structure predicted that the Y31C mutation will reduce the variant's stability. Expression of the FTL Y31C variant resulted in significantly lower cellular ferritin levels compared with the expression of wild‐type FTL (FTL WT ). Proteasomal inhibition significantly increased the initial levels of FTL Y31C , but could not protect FTL Y31C subunits from successive degradation. Further, variant subunits successfully incorporated into hetero‐polymeric nanocages in the presence of sufficient levels of FTH1. However, FTL Y31C subunits poorly assembled into nanocages when FTH1 subunit levels were low. These results indicate an increased susceptibility of unassembled monomeric FTL Y31C subunits to proteasomal degradation. The decreased cellular assembly of FTL Y31C ‐rich nanocages may explain the low serum ferritin levels in this patient and emphasize the importance of a broader diagnostic approach of hypoferritinemia without anemia, before IV iron supplementation.
Thinking Differently—On Solitude and Productivism—Reply
Authors: Shaurya Taran
Journal: JAMA Internal Medicine (2023)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study
Authors: Hisham Mehanna, Davy Rapozo, Sandra V. von Zeidler, Kevin J. Harrington, Stuart C. Winter, Andrew Hartley, Paul Nankivell, Andrew G. Schache, Philip Sloan, Edward W. Odell, Selvam Thavaraj, Keith D. Hunter, Ketan A. Shah, Gareth J. Thomas, Anna Long, Rasoul Amel-Kashipaz, Rachel M. Brown, Brendan Conn, Gillian L. Hall, Paul Matthews, Justin Weir, Yen Yeo, Miranda Pring, Catharine M.L. West, James McCaul, Pawel Golusinski, Alice Sitch, Rachel Spruce, Nikolaos Batis, Jennifer L. Bryant, Jill M. Brooks, Terence M. Jones, Francesca Buffa, Syed Haider, Max Robinson
Journal: Clinical Cancer Research (2023)

Abstract Purpose: While there are several prognostic classifiers, to date, there are no validated predictive models that inform treatment selection for oropharyngeal squamous cell carcinoma (OPSCC). Our aim was to develop clinical and/or biomarker predictive models for patient outcome and treatment escalation for OPSCC. Experimental Design: We retrospectively collated clinical data and samples from a consecutive cohort of OPSCC cases treated with curative intent at ten secondary care centers in United Kingdom and Poland between 1999 and 2012. We constructed tissue microarrays, which were stained and scored for 10 biomarkers. We then undertook multivariable regression of eight clinical parameters and 10 biomarkers on a development cohort of 600 patients. Models were validated on an independent, retrospectively collected, 385-patient cohort. Results: A total of 985 subjects (median follow-up 5.03 years, range: 4.73–5.21 years) were included. The final biomarker classifier, comprising p16 and survivin immunohistochemistry, high-risk human papillomavirus (HPV) DNA in situ hybridization, and tumor-infiltrating lymphocytes, predicted benefit from combined surgery + adjuvant chemo/radiotherapy over primary chemoradiotherapy in the high-risk group [3-year overall survival (OS) 63.1% vs. 41.1%, respectively, HR = 0.32; 95% confidence interval (CI), 0.16–0.65; P = 0.002], but not in the low-risk group (HR = 0.4; 95% CI, 0.14–1.24; P = 0.114). On further adjustment by propensity scores, the adjusted HR in the high-risk group was 0.34, 95% CI = 0.17–0.67, P = 0.002, and in the low-risk group HR was 0.5, 95% CI = 0.1–2.38, P = 0.384. The concordance index was 0.73. Conclusions: We have developed a prognostic classifier, which also appears to demonstrate moderate predictive ability. External validation in a prospective setting is now underway to confirm this and prepare for clinical adoption.
Newborn and Early Infant Outcomes Following Maternal COVID-19 Vaccination During Pregnancy
Authors: Sarah C. J. Jorgensen, Samantha S. M. Drover, Deshayne B. Fell, Peter C. Austin, Rohan D’Souza, Astrid Guttmann, Sarah A. Buchan, Sarah E. Wilson, Sharifa Nasreen, Kevin L. Schwartz, Mina Tadrous, Kumanan Wilson, Jeffrey C. Kwong
Journal: JAMA Pediatrics (2023)

Importance The study team previously showed that maternal mRNA COVID-19 vaccination during pregnancy confers protection against SARS-CoV-2 infection and COVID-19–related hospital admission in newborns and young infants. In this study, the study team evaluated newborn and early infant safety outcomes following maternal messenger RNA (mRNA) COVID-19 vaccination during pregnancy, for which there is limited comparative epidemiological evidence. Objective To determine if maternal mRNA COVID-19 vaccination during pregnancy is associated with adverse newborn and early infant outcomes. Design, Setting, and Participants This population-based retrospective cohort study took place in Ontario, Canada, using multiple linked health administrative databases. Singleton live births with an expected delivery date between May 1, 2021, and September 2, 2022, were included. Data were analyzed from January 2023 through March 2023. Exposure Maternal mRNA COVID-19 vaccination (1 or more doses) during pregnancy Main Outcomes and Measures Severe neonatal morbidity (SNM), neonatal death, neonatal intensive care unit (NICU) admission, neonatal readmission, and hospital admission up to 6 months of age. The study team calculated inverse probability of treatment weighted risk ratios (RRs) and fit weighted Cox proportional hazards regression models comparing outcomes in infants of mothers who received COVID-19 vaccination during pregnancy with those who received no COVID-19 vaccine doses before delivery. Results In total, 142 006 infants (72 595 male [51%]; mean [SD] gestational age at birth, 38.7 [1.7] weeks) were included; 85 670 were exposed to 1 or more COVID-19 vaccine doses in utero (60%). Infants of vaccinated mothers had lower risks of SNM (vaccine exposed 7.3% vs vaccine unexposed 8.3%; adjusted RR [aRR], 0.86; 95% CI, 0.83-0.90), neonatal death (0.09% vs 0.16%; aRR, 0.47; 95% CI, 0.33-0.65), and NICU admission (11.4% vs 13.1%; aRR, 0.86; 95% CI, 0.83-0.89). There was no association between maternal vaccination during pregnancy and neonatal readmission (5.5% vs 5.1%; adjusted hazard ratio, 1.03; 95% CI, 0.98-1.09) or 6-month hospital admission (8.4% vs 8.1%; adjusted hazard ratio, 1.01; 95% CI, 0.96-1.05). Conclusions and Relevance In this population-based cohort study in Ontario, Canada, maternal mRNA COVID-19 vaccination during pregnancy was associated with lower risks of SNM, neonatal death, and NICU admission. In addition, neonatal and 6-month readmissions were not increased in infants of mothers vaccinated during pregnancy.
The Interaction of Acute Kidney Injury with Resuscitation Strategy in Sepsis: A Secondary Analysis of a Multicenter, Phase 3, Randomized Clinical Trial (CLOVERS)
Authors: Ayesha Khader, Leila R. Zelnick, Neha A. Sathe, Bryan R. Kestenbaum, Jonathan Himmelfarb, Nicholas J. Johnson, Nathan I. Shapiro, Ivor S. Douglas, Catherine L. Hough, Pavan K. Bhatraju
Journal: American Journal of Respiratory and Critical Care Medicine (2023)

"The Interaction of Acute Kidney Injury with Resuscitation Strategy in Sepsis: A Secondary Analysis of a Multicenter, Phase 3, Randomized Trial (CLOVERS)." American Journal of Respiratory and Critical Care Medicine, 0(ja), pp.
Hypertension Diagnosis, Treatment, and Control in India
Authors: Jithin Sam Varghese, Nikhil Srinivasapura Venkateshmurthy, Nikkil Sudharsanan, Panniyammakal Jeemon, Shivani A. Patel, Harsha Thirumurthy, Ambuj Roy, Nikhil Tandon, K. M. Venkat Narayan, Dorairaj Prabhakaran, Mohammed K. Ali
Journal: JAMA Network Open (2023)

Hypertension is a major cause of morbidity and mortality worldwide. Previous efforts to characterize gaps in the hypertension care continuum-including diagnosis, treatment, and control-in India did not assess district-level variation. Local data are critical for planning, implementation, and monitoring efforts to curb the burden of hypertension.To examine the hypertension care continuum in India among individuals aged 18 to 98 years.The nationally representative Fifth National Family Health Survey study was conducted in 2 phases from June 17, 2019, to March 21, 2020, and from November 21, 2020, to April 30, 2021, among 1 895 297 individuals in 28 states, 8 union territories, and 707 districts of India.District and state of residence, urban classification, age (18-39, 40-64, and ≥65 years), sex, and household wealth quintile.Hypertension was defined as a self-reported diagnosis or a newly measured blood pressure of 140/90 mm Hg or more. The proportion of individuals diagnosed (self-reported), the proportion of individuals treated among those diagnosed (self-reported medication use), and the proportion of individuals with blood pressure control among those treated (blood pressure <140/90 mm Hg [aged 18-79 years] or <150/90 mm Hg [aged ≥80 years]) were calculated based on national guidelines. Age-standardized estimates of treatment and control were also provided among the total with hypertension. To assess differences in the care continuum between or within states (ie, between districts), the variance was partitioned using generalized linear mixed models.Of the 1 691 036 adult respondents (52.6% women; mean [SD] age, 41.6 [16.5] years), 28.1% (95% CI, 27.9%-28.3%) had hypertension, of whom 36.9% (95% CI, 36.4%-37.3%) received a diagnosis. Among those who received a diagnosis, 44.7% (95% CI, 44.1%-45.3%) reported taking medication (corresponding to 17.7% [95% CI, 17.5%-17.9%] of the total with hypertension). Among those treated, 52.5% (95% CI, 51.7%-53.4%) had blood pressure control (corresponding to 8.5% [95% CI, 8.3%-8.6%] of the total with hypertension). There were substantial variations across districts in blood pressure diagnosis (range, 6.3%-77.5%), treatment (range, 8.7%-97.1%), and control (range, 2.7%-76.6%). Large proportions of the variation in hypertension diagnosis (94.7%), treatment (93.6%), and control (97.3%) were within states, not just between states.In this cross-sectional survey study of Indian adults, more than 1 in 4 people had hypertension, and of these, only 1 in 3 received a diagnosis, less than 1 in 5 were treated, and only 1 in 12 had blood pressure control. National mean values hide considerable state-level and district-level variation in the care continuum, suggesting the need for targeted, decentralized solutions to improve the hypertension care continuum in India.
Lasting Adverse Effects of Low-Level Lead Exposure on Cognition and Heritable Susceptibilities
Authors: Howard Hu
Journal: JAMA Network Open (2023)

Zhenxian Jia, PhD; Hongling Zhang, MS; Ling Yu, PhD; Feng Qiu, PhD; Yiqing Lv, PhD; Jing Guan, MS; Huiqing Gang, MPH; Jingwen Zuo, MPH; Tongzhang Zheng, PhD; Hongxiu Liu, PhD; Wei Xia, PhD; Shunqing Xu, PhD; Yuanyuan Li, PhD
Safety and Efficacy of Topiramate in Individuals With Cryptogenic Sensory Peripheral Neuropathy With Metabolic Syndrome
Authors: A. Gordon Smith, J. Robinson Singleton, Adrienne Aperghis, Christopher S. Coffey, Peter Creigh, Merit Cudkowicz, Robin Conwit, Dixie Ecklund, Janel K. Fedler, Anna Gudjonsdottir, Peter Hauer, David N. Herrmann, Marianne Kearney, John Kissel, Elizabeth Klingner, Adam Quick, Cathy Revere, Amro Stino, Elias Sirja, Aaron Vinik, Amanda Peltier, Mamatha Pasnoor, Brian Callaghan, Daniella Maria Menichella, Chris Nance, Reza Seyedsadiadi, Mario Saporta, Lauren Phillips, Eroboghene Ubogu, Shawn Bird, Stefanie Geisler, Glenn Lopate, James Caress, Thomas Brannagan, Kelly Gwathmey, Erik Ortega, Tahseen Mozaffar, Mark Milstein, Dianna Quan, Janet Snowden, Julie Charles, Elizabeth Wood, Joan Mountain, Christine Annis, Debra Guntrum, Cynthia Gibson, Noreen Connolly, Steffen Behrens-Spraggins, Mariana Doudova, Candice Dolan, Amy Bartlett, Julie Agriesti, Carolina Casellini, Michael Bailey, Kelly Lowen, Tricia McKinney, Sally Furukawa, Alyssa Lackey, Tina Liu, Katheryn Jennens, Samantha Colgan, Amanda Rasnake, Meghan Stelzer, Courtney Graft, Tina Ward, Taylor Coffey, Cosette Burian, Monika Szela, Justine Houseman, Connie Casale, Jeri Sieren, Heena Olalde, Nicole Kressin, Loriane Brenner, Peter James, Claudia Maria Brito Pires, Natalie Grant, Wendy Levy, Julie Steele, Maria Paredes, Steven Hopkins, Amruta Joshi, William Thayer, Amy Conger, Jovana Valdez, Melanie Benge, Elizabeth Harders, Kelsey Moulton, Mengesha Teshome, Nikki Bauer, Kelly Streckfuss, Summer Harris, Jessyca Clemons, Karie Bond, Arreum Kim, Raisy Fayerman, Johana Gonzalez, Joyce Moran, Pranay Vissa, Bridget Wilkins, Nicole Turcotte, Stephanie Strong, Isela Hernandez, Marie Wencel, Diana Moyer, Melanie Meton, Elena Slabbekoorn, Rehana Rafi, Diane Capobianco, Connie Parido
Journal: JAMA Neurology (2023)

Cryptogenic sensory peripheral neuropathy (CSPN) is highly prevalent and often disabling due to neuropathic pain. Metabolic syndrome and its components increase neuropathy risk. Diet and exercise have shown promise but are limited by poor adherence.